{"id":77803,"date":"2024-03-13T03:28:34","date_gmt":"2024-03-13T08:28:34","guid":{"rendered":"https:\/\/equitynewsreport.com\/jmp-starts-prelude-therapeuticscites-cancer-tech-promise\/"},"modified":"2024-03-13T03:28:34","modified_gmt":"2024-03-13T08:28:34","slug":"jmp-starts-prelude-therapeuticscites-cancer-tech-promise","status":"publish","type":"post","link":"https:\/\/equitynewsreport.com\/h\/jmp-starts-prelude-therapeuticscites-cancer-tech-promise\/","title":{"rendered":"JMP starts Prelude Therapeutics,cites cancer tech promise"},"content":{"rendered":"<div readability=\"67\">\n<div id=\"imgCarousel\" class=\"imgCarousel\">\n<img decoding=\"async\" alt=\"JMP starts Prelude Therapeutics,cites cancer tech promise\" id=\"carouselImage\" src=\"https:\/\/i-invdn-com.investing.com\/news\/LYNXMPEA7D094_L.jpg\"><br \/>\n<span class=\"text\">\u00a9 Reuters. <\/span><br \/>\n<i class=\"imgGrad\"><\/i>\n<\/div>\n<p>On Wednesday, JMP Securities initiated coverage on shares of Prelude Therapeutics (NASDAQ:PRLD), assigning a Market Outperform rating and setting a price target of $7.00. The firm&#8217;s assessment is based on a detailed analysis of the company&#8217;s earnings per share and revenue potential. <\/p>\n<p>Prelude Therapeutics is currently developing innovative cancer treatments and has caught the attention of the industry with its novel PROTAC-targeting SMARCA2 technology. This approach utilizes the concept of synthetic lethality to target the interdependence of two genes for cell survival.<\/p>\n<p>Prelude&#8217;s preclinical findings have shown significant promise, suggesting that their new target could play a crucial role in cancer therapy. The company is advancing two assets through clinical trials, with initial results anticipated in the second half of 2024. JMP Securities highlighted the company&#8217;s strong cash position, standing at $233 million, as a key factor in their optimistic outlook.<\/p>\n<p>The firm&#8217;s analysis suggests that Prelude&#8217;s stock has approximately a 51% downside risk, with a bear case price target of $2.00, and an upside potential of around 120%, with a bull case target of $9.00. The current price target reflects a balanced view of these potential outcomes, underscoring the firm&#8217;s confidence in the company&#8217;s prospects.<\/p>\n<p>Investors and market watchers will be keeping a close eye on Prelude Therapeutics as it continues to progress through its clinical trials. The outcomes of these trials will be pivotal in determining the future trajectory of the company&#8217;s stock and its role in the oncology sector. With a significant upside highlighted by JMP Securities, Prelude Therapeutics represents a company to watch in the coming months.<\/p>\n<p><em>This article was generated with the support of AI and reviewed by an editor. For more information see our T&#038;C.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u00a9 Reuters. On Wednesday, JMP Securities initiated coverage on shares of Prelude Therapeutics (NASDAQ:PRLD), assigning a Market Outperform rating and setting a price target of $7.00. The firm&#8217;s assessment is based on a detailed analysis of the company&#8217;s earnings per share and revenue potential. Prelude Therapeutics is currently developing innovative cancer treatments and has caught the attention of the industry with its novel PROTAC-targeting SMARCA2 technology. This approach utilizes the concept of synthetic lethality to target the interdependence of two genes for cell survival. Prelude&#8217;s preclinical findings have shown significant promise, suggesting that their new target could play a crucial [&hellip;]<\/p>\n","protected":false},"author":5,"featured_media":77804,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,49,50,3],"tags":[],"_links":{"self":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77803"}],"collection":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/comments?post=77803"}],"version-history":[{"count":0,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/posts\/77803\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media\/77804"}],"wp:attachment":[{"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/media?parent=77803"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/categories?post=77803"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/equitynewsreport.com\/h\/wp-json\/wp\/v2\/tags?post=77803"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}